Office of Research & Development |
  |
Talk to the Veterans Crisis Line now
An official website of the United States government
Project Number: | IK2BX004940-01 |
| Title: | Development of new drugs for Toxoplasma by advancing hits from the Global Health Chemical Diversity Library |
| Principal Investigator: | Phil Alday |
| Location: | Portland, OR |
| Congressional District Code: | 3 |
| Research Service: | Biomedical Laboratory R&D |
| Project Period: | January 2020 - December 2024 |
| FY 2021 Funding Amount: | $289,825 |
| Total Award Amount (all years): |
$1,482,564 |
| Abstract: |
View full abstract and other project information on NIH RePORTER Go To NIH RePORTER Excerpt: Toxoplasma gondii is a prolific eukaryotic parasite that is widely distributed throughout the world. Infection with T. gondii can cause severe and potentially fatal brain and eye disease, especially in immunocompromised individuals. Worldwide, T. gondii is also a leading infectious cause of blindness in otherwise healthy individuals. The current first-line therapy for T. gondii is a combination of the drugs pyrimethamine and sulfadiazine, but this regimen suffers from a number of shortcomings. The... |